What is claimed is:

1. An antibody which specifically binds to CD3, wherein the antibody comprises:

   a. a heavy chain variable (VH) region comprising a VH complementarity determining region one (VH CDR1), a VH complementarity determining region two (VH CDR2), and a VH complementarity determining region three (VH CDR3) of the VH sequence shown in SEQ ID NO: 4 and

   b. a light chain variable (VL) region comprising a VL complementarity determining region one (VL CDR1), a VL complementarity determining region two (VL CDR2), and a VL complementarity determining region three (VL CDR3) of the VL sequence shown in SEQ ID NO: 3.

2. The antibody of claim 1, wherein the antibody comprises:

   a. a VH region comprising (i) a VH CDR1 comprising a sequence of SEQ ID NO: 13, 14, or 15; (ii) a VH CDR2 comprising a sequence of SEQ ID NO: 19 or 20; and iii) a VH CDR3 comprising a sequence of SEQ ID NO: 18; and

   b. a VL region comprising (i) a VL CDR1 comprising a sequence of SEQ ID NO: 29; (ii) a VL CDR2 comprising a sequence of SEQ ID NO: 27; and (iii) a VL CDR3 comprising a sequence of SEQ ID NO: 28.

3. The antibody of claim 1 or 2, wherein:

   a. the VH region comprises a sequence of SEQ ID NO: 4; and

   b. the VL region comprises a sequence of SEQ ID NO: SEQ ID NO: 3.

4. The antibody of any one of claims 1 to 3, wherein the antibody is selected from the group consisting of a Fab, a Fab fragment, a $F(ab)_2$ fragment, an Fv fragment, a single chain Fv fragment, a disulfide stabilized Fv fragment, a single-chain antibody, a monoclonal antibody, a chimeric antibody, a bispecific antibody, a trispecific antibody, a multispecific antibody, a bispecific heterodimeric diabody, a bispecific heterodimeric IgG, a polyclonal antibody, a labeled antibody, a humanized antibody, a human antibody, and fragments thereof.

5. The antibody of claim 4, wherein the antibody is a bispecific antibody, optionally wherein the bispecific antibody specifically binds to a tumor antigen.

6. A pharmaceutical composition comprising the antibody of any one of claims 1 to 5, and a pharmaceutically acceptable carrier.

7. A polynucleotide comprising a nucleotide sequence encoding the antibody of any one of claims 1 to 5.

8. A vector comprising the polynucleotide of claim 7.

9. A host cell comprising the vector of claim 8.

10. The host cell of claim 9 that recombinantly produces the antibody of any one of claims 1 to 5.

11. The host cell of claim 9 or 10, wherein the host cell is selected from the group consisting of bacterial cell lines, mammalian cell lines, insect cell lines, and yeast cell lines, optionally wherein the mammalian cell line is a CHO cell line.

12. A method of producing an antibody comprising culturing the host cell of any one of claims 9 to 11, under conditions that result in production of the antibody of any of claims 1 to 5, and purifying the antibody from the culture supernatant.

13. The antibody of any one of claims 1 to 5, or the pharmaceutical composition of claim 6, for use in therapy.

14. The antibody or the pharmaceutical composition for use of claim 13, wherein the therapy comprises activation of a cytolytic T cell response.

15. The antibody of any one of claims 1 to 5 or the pharmaceutical composition of claim 6, for use in a method of modulating a T cell mediated immune response in a subject in need thereof.

16. The antibody of any one of claims 1 to 5 or the pharmaceutical composition of claim 6, for use in a method of inhibiting growth of tumor cells in a subject.

17. The antibody of any one of claims 1 to 5 or the pharmaceutical composition of claim 6, for use in treating cancer, optionally wherein the cancer is selected from the

group consisting of breast, ovarian, thyroid, prostate, cervical, lung, bladder, endometrial, head and neck, testicular, glioblastoma cancer and cancer of digestive system.

18. The antibody or the pharmaceutical composition for use according to claim 17, wherein the T cell mediated immune response is modulated or wherein the growth of tumor cells is inhibited.